Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors
Clinical trial NCT05101109 · COMPLETED
Trial details
- NCT number
- NCT05101109
- Sponsor
- ABL Bio, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-06
- Primary completion
- 2024-05-14
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.